Apollo Cancer Centre Introduces South Asia’s First, Most Advanced CyberKnife System

Bhubaneswar: Ushering in another new era in healthcare, Apollo Cancer Centre, Chennai has introduced South Asia’s first CyberKnife—CyberKnife® S7™ FIM Robotic Radio Surgery System, offering a revolutionary treatment modality of cancerous and non-cancerous tumors. The introduction of the CyberKnife System marks a transformative moment for cancer care and technology.

The CyberKnife® S7™ FIM System is a non-invasive treatment for cancerous and non-cancerous tumors and other conditions where radiation therapy is indicated. It is used to treat conditions throughout the body including brain, lung, spine, prostate and abdominal cancers, and may be an alternative to surgery for patients who have inoperable or surgically complex tumors. Even patients previously treated with radiation, who have metastatic lesions or with recurrent cancers can receive CyberKnife treatment.

Dr Mahadev Potharaju, Senior Consultant – Radiation Oncology, elaborated, “CyberKnife® S7™ FIM treatments are typically performed in 1 to 5 sessions. The treatment duration typically ranges from 30 to 90 minutes, during which 100 to 200 radiation beams are administered from various angles. Each beam lasts for approximately 10 to 15 seconds. Treatment sessions are non-invasive outpatient procedures, and no anaesthesia or incisions are required, enabling most patients to continue with daily activities over the course of treatment.”

Patient Benefits of CyberKnife® S7™ FIM Robotic Radio Surgery System

• Precise, effective & targeted treatment enabling a faster return to everyday life
• Provides improved quality of life
• Lesser treatment sessions
• Precisely treats almost any tumor/cancer indication & complexity
• Excellent long-term cancer control through a non-surgical, non-invasive/painless outpatient procedure
• Minimal dose to healthy tissues with fewer side effects
• Greater patient comfort – the only technology that enables patients to breathe freely during radiotherapy
• Lower risk of recurrence